A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.
Georg A. Bjarnason
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Naveen S. Basappa
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Jennifer J. Knox
Research Funding - Pfizer
Christian K. Kollmannsberger
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
M. Neil Neil Reaume
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Pawel Zalewski
No relevant relationships to disclose
Robyn Jane Macfarlane
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Mary J. MacKenzie
Honoraria - Pfizer
Sebastien J. Hotte
No relevant relationships to disclose
Daniel Yick Chin Heng
Consultant or Advisory Role - Pfizer
Denis Soulieres
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Jessie Miller
No relevant relationships to disclose